FY2026 Earnings Estimate for InflaRx Issued By HC Wainwright

InflaRx N.V. (NASDAQ:IFRX) – Investment analysts at HC Wainwright upped their FY2026 EPS estimates for InflaRx in a research report issued to clients and investors on Tuesday, November 3rd. HC Wainwright analyst M. Keller now forecasts that the company will earn ($0.22) per share for the year, up from their previous forecast of ($0.35). The consensus estimate for InflaRx’s current full-year earnings is ($0.31) per share. HC Wainwright also issued estimates for InflaRx’s Q4 2026 earnings at ($0.04) EPS, FY2027 earnings at ($0.25) EPS and FY2028 earnings at ($0.27) EPS.

InflaRx (NASDAQ:IFRX) last released its quarterly earnings results on Tuesday, November 3rd. The company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.06) by $0.04.

A number of other research firms have also issued reports on IFRX. Cantor Fitzgerald increased their target price on InflaRx from $4.00 to $6.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Needham & Company LLC started coverage on InflaRx in a research report on Monday, September 14th. They set a “buy” rating and a $8.00 price target for the company. Zacks Research cut InflaRx from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of InflaRx in a research report on Monday, September 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $7.43.

InflaRx Stock Performance

Shares of InflaRx stock opened at $1.48 on Thursday. InflaRx has a 1 year low of $0.80 and a 1 year high of $2.95. The business has a 50 day moving average price of $1.83 and a 200 day moving average price of $1.63.

Hedge Funds Weigh In On InflaRx

Several large investors have recently added to or reduced their stakes in IFRX. Montanova Capital LLC boosted its stake in InflaRx by 189.1% in the 2nd quarter. Montanova Capital LLC now owns 22,933,910 shares of the company’s stock worth $51,372,000 after buying an additional 15,000,000 shares during the last quarter. Spruce Street Capital LP purchased a new stake in InflaRx in the 2nd quarter valued at about $11,988,924. ADAR1 Capital Management LLC purchased a new stake in InflaRx in the 2nd quarter valued at about $6,720,000. Jefferies Financial Group Inc. acquired a new position in shares of InflaRx during the 2nd quarter valued at about $1,737,000. Finally, T3 Companies LLC increased its stake in shares of InflaRx by 32.9% during the 3rd quarter. T3 Companies LLC now owns 440,000 shares of the company’s stock valued at $792,000 after acquiring an additional 108,986 shares during the last quarter. 42.39% of the stock is currently owned by hedge funds and other institutional investors.

Key InflaRx News

Here are the key news stories impacting InflaRx this week:

• Positive Sentiment: InflaRx plans two Phase 2 AAV trials in 2027, including a study in patients with kidney involvement and an open-label study testing whether izicopan can replace corticosteroids. The company expects initial results in 2028. InflaRx Capital Markets Day announcement
• Positive Sentiment: The company estimates izicopan could reach peak AAV sales of $1.5 billion to $2 billion, while acknowledging that this is a forecast rather than established commercial performance. It also plans studies in aHUS and IgA nephropathy. RTTNews report on izicopan plans
• Positive Sentiment: InflaRx reported €153.3 million in cash, cash equivalents and marketable securities at September 30, which it expects to fund operations and clinical development through 2029. Third-quarter EPS was a loss of $0.02, narrower than analysts’ expected $0.04 loss. Third-quarter earnings report
• Neutral Sentiment: The company also announced an advisory board of experts in vasculitis, nephrology and immune-mediated kidney disease, adding specialist input as it develops the program. Izicopan program and advisory board announcement
• Negative Sentiment: The main AAV trial data are not expected until 2028, and the sales opportunity depends on successful future studies and commercialization. That leaves substantial development and execution risk before the projections can be validated.

About InflaRx

InflaRx N.V. (NASDAQ: IFRX) is a biopharmaceutical company focused on developing therapies for inflammatory and autoimmune diseases. Founded in 2007 and headquartered in Jena, Germany, the company’s research is centered on the complement system, an important part of the immune response. InflaRx seeks to selectively block complement component C5a, a potent inflammatory mediator, while preserving other aspects of immune-system function.

The company’s lead product, vilobelimab, is a first-in-class monoclonal antibody designed to inhibit C5a.